Say it with us: IQVIA is the new Quin­tiles and IMS Health

A lo­go sign out­side of the head­quar­ters of Quin­tiles Transna­tion­al in Durham, North Car­oli­na on No­vem­ber 29, 2015 AP Im­ages

A year af­ter its trail­blaz­ing merg­er, Quin­tiles­IMS, the world’s largest clin­i­cal out­sourc­ing firm will now be known as IQVIA, the com­pa­ny an­nounced to­day.

The brand new IQVIA web site fea­tures an au­r­al pro­nounc­er but­ton to avoid any con­fu­sion as to how it should sound: “I-Q-via.”

“IQVIA may be ground­ed in the in­tel­li­gence and ca­pa­bil­i­ties of I and Q, but it is ‘via’ the path for­ward that we hope to in­spire and ig­nite re­al change for health­care stake­hold­ers,” a spokesper­son told End­points News.

The ‘I’ and the ‘Q’ harken back to a time when a hand­ful of an­a­lyt­ics shops owned all the post-ap­proval da­ta while CROs sim­ply stayed in their lane and ran clin­i­cal tri­als, a by­gone era dom­i­nat­ed by the now ful­ly sub­sumed IMS Health and Quin­tiles. The not-long-for-this-world Quin­tiles­IMS brand op­er­at­ed for over a year, mak­ing way for a fresh new name the com­pa­ny hopes broad­ens bio­phar­ma’s per­cep­tions of it. Since com­bin­ing, the com­pa­ny has “worked to in­te­grate [their] ca­pa­bil­i­ties in ad­vanced an­a­lyt­ics, lead­ing tech­nolo­gies and ther­a­peu­tic ex­per­tise in­to pow­er­ful, dif­fer­en­ti­at­ed of­fer­ings.”

The de­ci­sion to merge two oth­er­wise dis­parate op­er­a­tions sig­naled a new di­rec­tion for the clin­i­cal out­sourc­ing in­dus­try, where con­sol­i­da­tion and ex­pan­sion in­to new da­ta-dri­ven mar­kets is the name of the game now. And re­brand­ing sea­son isn’t quite over yet in the CRO world. The re­cent­ly merged INC Re­search and in­Ven­tiv Health, #5 on our list of the top 10 CROs, are ex­pect­ed to un­veil their new com­bined brand in 2018.

Ari Bous­bib

IQVIA will trade on the New York Stock Ex­change un­der the new name and new tick­er sym­bol $IQC start­ing on No­vem­ber 15, 2017. Un­til then, the com­pa­ny will con­tin­ue to be list­ed un­der Quin­tiles­IMS and sym­bol $Q.

“To­day is a defin­ing mo­ment for our or­ga­ni­za­tion as we in­tro­duce a new name that aligns with our vi­sion to help stake­hold­ers dri­ve health­care for­ward,” said CEO Ari Bous­bib in a state­ment. “Our vi­sion is to out­pace the in­evitable progress of change across the life sci­ences and ac­cel­er­ate our abil­i­ty to em­pow­er health­care de­ci­sion mak­ers to meet the fu­ture head on.”

The com­pa­ny’s mar­ket cap has risen from $20.74 bil­lion in Au­gust to $23.03 bil­lion.

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

As Themis gears up for a Phase III trial of its chikungunya vaccine, the Vienna-based biotech has closed out €40 million ($44 million) to foot the clinical and manufacturing bills.

Its heavyweight partners at Merck — which signed a pact around a mysterious “blockbuster indication” last month — jumped into the Series D, led by new investors Farallon Capital and Hadean Ventures. Adjuvant Capital also joined, as did current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences.